Erratum to "Abiraterone Acetate Attenuates SARS-CoV-2 Replication by Interfering with the Structural Nucleocapsid Protein" [Biomol Ther 30(5), 427-434 (2022)]

Jinsoo Kim; Seok Young Hwang; Dongbum Kim; Minyoung Kim; Kyeongbin Baek; Mijeong Kang; Seungchan An; Junpyo Gong; Sangkyu Park; Mahmoud Kandeel; Younghee Lee; Minsoo Noh; Hyung-Joo Kwon

doi:10.4062/biomolther.2024.005

Biomolecules & Therapeutics 2025; 33(1): 231-232 https://doi.org/10.4062/biomolther.2024.005

Erratum to "Abiraterone Acetate Attenuates SARS-CoV-2 Replication by Interfering with the Structural Nucleocapsid Protein" [Biomol Ther 30(5), 427-434 (2022)]

Jinsoo Kim^1,†, Seok Young Hwang^2,†, Dongbum Kim^3,†, Minyoung Kim¹, Kyeongbin Baek¹, Mijeong Kang¹, Seungchan An², Junpyo Gong², Sangkyu Park⁴, Mahmoud Kandeel^5,6, Younghee Lee⁴, Minsoo Noh^2,* and Hyung-Joo Kwon^1,3,*

¹Department of Microbiology, College of Medicine, Hallym University, Chuncheon 24252,
²College of Pharmacy, Natural Products Research Institute, Seoul National University, Seoul 08826,
³Institute of Medical Science, College of Medicine, Hallym University, Chuncheon 24252,
⁴Department of Biochemistry, College of Natural Sciences, Chungbuk National University, Cheongju 28644, Republic of Korea
⁵Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al-hofuf 31982, Saudi Arabia
⁶Department of Pharmacology, Faculty of Veterinary Medicine, Kafrelshikh University, Kafrelshikh 33516, Egypt

E-mail: hjookwon@hallym.ac.kr (Kwon HJ), minsoonoh@snu.ac.kr (Noh M)
Tel: +82-33-248-2635 (Kwon HJ), +82-02-880-2481 (Noh M)
Fax: +82-33-241-3640 (Kwon HJ), +82-02-880-2482 (Noh M)

^†The first three authors contributed equally to this work.

Published online: January 1, 2025.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

DOI of original article : https://doi.org/10.4062/biomolther.2022.037

Body

The authors request corrections to the chemical name (Abiraterone Acetate) in Fig. 2B on page 430 and the confocal images in Fig. 5A on page 432. Additionally, corrections are made to the 12th–15th lines in the right column of the Results section on page 430 and the 11th–13th lines in the left column of the Discussion section on page 433. The error in the 4th line of the Figure 2 legend is also corrected. Furthermore, three spelling errors in the term ‘plaque’ were identified. These errors do not affect the conclusions of the article. The authors sincerely apologize for this inadvertent mistake and any inconvenience caused.

Figure 1. Fig. 2

Figure 2. Fig. 5

RESULTS

The 12th-15th lines in the right column of the Results section on Page 430.

“However, two drugs, atovaquone and digoxin, tended to reduce the size of the SARS-CoV-2 viral plaques in the preliminary screening assays (Fig. 2A-2C).”

The 4th line of Fig. 2 legend on page 430.

“These data show only 4 representatives of the 12 FDA-approved drugs.”

DISCUSSION

The 11th-13th lines in the left column of the Discussion section on Page 433.

“Atovaquone and digoxin were likely to reduce the size of the viral plaques.”